Document Detail


Should lamivudine monotherapy be stopped or continued in patients infected with hepatitis B with favorable responses after more than 5 years of treatment?
MedLine Citation:
PMID:  23154874     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Regarding the limited evidence for determining the optimal duration of antiviral treatment for hepatitis B, the long-term outcome of patients with favorable responses to over 5 years of lamivudine monotherapy was investigated. Two hundred seventy-one patients who had received lamivudine for at least 5 years were enrolled. Ultimately, 72 patients without YMDD mutations and showing hepatitis B virus (HBV) DNA levels <2.5 pg/ml after 5 years of treatment were analyzed. Mean treatment duration with lamivudine was 9.1 ± 2.6 years. During the treatment, HBeAg and HBsAg loss/seroconversion rates were 95 and 6.9%, respectively. Decompensation and hepatocellular carcinoma (HCC) developed in 2.8 and 6.9% of patients, respectively. Old age and cirrhosis were risk factors for HCC development. Finally, 11.1% of patients developed YMDD mutations after 8.3 ± 2.4 years of treatment. There was no hepatic decompensation among the patients who developed delayed YMDD mutations. Sixteen patients who achieved a complete response stopped lamivudine and four patients showed relapses 10.3 ± 8.5 months after stopping lamivudine. Relapsed patients had more cirrhotic livers and higher rates of HBeAg positivity at 5 years than patients who maintained complete response. The present study suggests that patients who do not develop YMDD mutations over 5 years of treatment with lamivudine may continue lamivudine monotherapy until the loss of HBsAg. However, even for the patients showing favorable response over 5 years of treatment, those in older ages, with cirrhosis or who show poor HBeAg responses should be on careful monitoring to detect the development of viral mutations, relapse and even HCC. J. Med. Virol. 85:34-42, 2012. © 2012 Wiley Periodicals, Inc.
Authors:
Jung Hyun Kwon; Jeong Won Jang; Jong Young Choi; Chung-Hwa Park; Sun Hong Yoo; Si Hyun Bae; Seung Kew Yoon
Related Documents :
18788864 - Dental anomalies of number in the permanent dentition of patients with bilateral cleft ...
24598304 - Adherence to guidelines in the use of biological agents to treat psoriasis in brazil.
10102554 - Periodontal disease in patients with cleft palate and patients with unilateral and bila...
24478274 - Long-term outcome after liver transplantation for deoxyguanosine kinase (dguok) deficie...
14620434 - Vernal keratoconjunctivitis in nigerians: 109 consecutive cases.
16938154 - Pulmonary endarterectomy.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of medical virology     Volume:  85     ISSN:  1096-9071     ISO Abbreviation:  J. Med. Virol.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2012-11-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7705876     Medline TA:  J Med Virol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  34-42     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Wiley Periodicals, Inc.
Affiliation:
Department of Internal Medicine, The Catholic University of Korea, Seoul, Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical impact of A/H1/N1/09 influenza in patients with cirrhosis: Experience from a nosocomial clu...
Next Document:  Molecular analysis of hepatitis B virus in Bulgaria.